Dhan Chand

7PUBLICATIONS
108CO-AUTHORS
Tumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 25, 2026
Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.

|Jun 15, 2026
Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer.

|Dec 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Rebecca Porter, Bruno Bockorny, Bradley R Corr

|Nov 19, 2025
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling.

Carlos O Ontiveros, Myrna G Garcia, Clare E Murray

|Nov 14, 2025
The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity.

Eleni Chantzoura, Efrat Altman-Sharoni, Xavier Michelet

|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky, Gary K Schwartz, Michael S Gordon

Pageof 2

Frequent Collaborators

3 joint publications

Chloe Delepine

3 joint publications

Tyler J Curiel

3 joint publications

Kah Teong Soh

2 joint publications

Shanmugarajan Krishnan